Lilly Reports on Outcome of Phase III Study of Arzoxifene
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has announced that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene failed to demonstrate a statistically significant difference in key secondary efficacy endpoints, such as non-vertebral fractures, clinical vertebral fractures, cardiovascular events and cognitive function, compared to placebo.
Novartis drug Femara® is superior to tamoxifen after breast cancer surgery
- Details
- Category: Novartis
Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara® (letrozole) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive).
Nycomed reports sustained momentum in second quarter 2009
- Details
- Category: Nycomed
Nycomed reports sustained momentum in the second quarter 2009, with total net turnover increasing by 0.5% to €786.9 million excluding the impact of the Sepracor execution payment received in the first half of 2008. This performance is driven by Nycomed's Key Products. Pantoprazole turnover in Europe dropped only moderately after loosing patent protection in May.
Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research
- Details
- Category: Pfizer
Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc has entered into a collaboration with Private Access, the innovator in privacy-enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation.
US FDA approves Extavia® - the first in a new portfolio of planned MS therapies from Novartis
- Details
- Category: Novartis
The US Food and Drug Administration (FDA) has approved Extavia® (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.
Orphan Drug Designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS)
- Details
- Category: Product
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that Soliris(R) (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS).
Positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab)
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) has announced positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab) in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients
with metastatic colorectal cancer (mCRC). The co-primary endpoints, tested
independently, were progression-free and overall survival.
More Pharma News ...
- Pandemic (H1N1) 2009 influenza update
- Sanofi Pasteur submits supplemental application for A(H1N1) pandemic vaccine to U.S. FDA
- Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Next Generation Anti-Infective
- Studies Highlight Potential New Option in the Treatment of Bone Loss
- Sandoz launches first generic version of Prograf® capsules
- Abbott Partners With Beech-Nut to Provide New Parents with Nutrition Education and Support
- Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD